Edge Contrast of the FLAIR Hyperintense Region Predicts Survival in Patients with High-Grade Gliomas following Treatment with Bevacizumab

REFERENCES

1. 1.↵
   2. Wen PY,
   3. Kesari S

   . Malignant gliomas in adults. N Engl J Med 2008;359:492–507 doi:10.1056/NEJMra0708126 pmid:18669428

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Wen PY,
   3. Macdonald DR,
   4. Reardon DA, et al

   . Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol 2010;28:1963–72 doi:10.1200/JCO.2009.26.3541 pmid:20231676

   Abstract/FREE Full Text
3. 3.↵
   2. Chinot OL,
   3. Macdonald DR,
   4. Abrey LE, et al

   . Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep 2013;13:347 doi:10.1007/s11910-013-0347-2 pmid:23529375

   CrossRefPubMed
4. 4.↵
   2. Macdonald DR,
   3. Cascino TL,
   4. Schold SC, et al

   . Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277–80 doi:10.1200/JCO.1990.8.7.1277 pmid:2358840

   Abstract
5. 5.↵
   2. Galldiks N,
   3. Rapp M,
   4. Stoffels G, et al

   . Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging 2013;40:22–33 doi:10.1007/s00259-012-2251-4 pmid:23053325

   CrossRefPubMed
6. 6.↵
   2. Kothari PD,
   3. White NS,
   4. Farid N, et al

   . Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab. AJNR Am J Neuroradiol 2013;34:1752–57 doi:10.3174/ajnr.A3506 pmid:23578667

   Abstract/FREE Full Text
7. 7.↵
   2. Jeyaretna DS,
   3. Curry WT Jr.,
   4. Batchelor TT, et al

   . Exacerbation of cerebral radiation necrosis by bevacizumab. J Clin Oncol 2011;29:e159–62 doi:10.1200/JCO.2010.31.4815 pmid:21149667

   FREE Full Text
8. 8.↵
   2. Pope WB,
   3. Lai A,
   4. Nghiemphu P, et al

   . MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006;66:1258–60 doi:10.1212/01.wnl.0000208958.29600.87 pmid:16636248

   Abstract/FREE Full Text
9. 9.↵
   2. Pope WB,
   3. Xia Q,
   4. Paton VE, et al

   . Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology 2011;76:432–37 doi:10.1212/WNL.0b013e31820a0a8a pmid:21282590

   Abstract/FREE Full Text
10. 10.↵
    2. Norden AD,
    3. Young GS,
    4. Setayesh K, et al

    . Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779–87 doi:10.1212/01.wnl.0000304121.57857.38 pmid:18316689

    Abstract/FREE Full Text
11. 11.↵
    2. Gonzalez J,
    3. Kumar AJ,
    4. Conrad CA, et al

    . Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007;67:323–26 doi:10.1016/j.ijrobp.2006.10.010 pmid:17236958

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Hattingen E,
    3. Jurcoane A,
    4. Daneshvar K, et al

    . Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival. Neuro Oncol 2013;15:1395–404 doi:10.1093/neuonc/not105 pmid:23925453

    CrossRefPubMed
13. 13.↵
    2. Pope WB,
    3. Qiao XJ,
    4. Kim HJ, et al

    . Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol 2012;108:491–98 doi:10.1007/s11060-012-0847-y pmid:22426926

    CrossRefPubMed
14. 14.↵
    2. Huang RY,
    3. Rahman R,
    4. Ballman KV, et al

    . The impact of T2 FLAIR evaluation per RANO criteria on response assessment of recurrent glioblastoma patients treated with bevacizumab. Clin Cancer Res 2016;22:575–81 doi:10.1158/1078-0432.CCR-14-3040 pmid:26490307

    Abstract/FREE Full Text
15. 15.↵
    2. Sathornsumetee S,
    3. Desjardins A,
    4. Vredenburgh JJ, et al

    . Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 2010;12:1300–10 doi:10.1093/neuonc/noq099 pmid:20716591

    CrossRefPubMed
16. 16.↵
    2. Quant EC,
    3. Norden AD,
    4. Drappatz J, et al

    . Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 2009;11:550–55 doi:10.1215/15228517-2009-006 pmid:19332770

    CrossRefPubMed
17. 17.↵
    2. Drabycz S,
    3. Roldán G,
    4. de Robles P, et al

    . An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage 2010;49:1398–405 doi:10.1016/j.neuroimage.2009.09.049 pmid:19796694

    CrossRefPubMed
18. 18.↵
    2. Carpentier A,
    3. McNichols RJ,
    4. Stafford RJ, et al

    . Laser thermal therapy: real-time MRI-guided and computer-controlled procedures for metastatic brain tumors. Lasers Surg Med 2011;43:943–50 doi:10.1002/lsm.21138 pmid:22109661

    CrossRefPubMed
19. 19.↵
    2. Kim JW,
    3. Park CK,
    4. Park SH, et al

    . Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry 2011;82:224–27 doi:10.1136/jnnp.2009.178806 pmid:20587495

    Abstract/FREE Full Text
20. 20.↵
    2. Nowosielski M,
    3. Wiestler B,
    4. Goebel G, et al

    . Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology 2014;82:1684–92 doi:10.1212/WNL.0000000000000402 pmid:24727314

    CrossRefPubMed
21. 21.↵
    2. Taillibert S,
    3. Vincent LA,
    4. Granger B, et al

    . Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology 2009;72:1601–06 doi:10.1212/WNL.0b013e3181a413be pmid:19414728

    Abstract/FREE Full Text
22. 22.↵
    2. Artzi M,
    3. Bokstein F,
    4. Blumenthal DT, et al

    . Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study. Eur J Radiol 2014;83:1250–56 doi:10.1016/j.ejrad.2014.03.026 pmid:24809637

    CrossRefPubMed
23. 23.↵
    2. Kinoshita M,
    3. Sakai M,
    4. Arita H, et al

    . Introduction of high throughput magnetic resonance T2-weighted image texture analysis for WHO grade 2 and 3 gliomas. PLoS One 2016;11:e0164268 doi:10.1371/journal.pone.0164268 pmid:27716832

    CrossRefPubMed
24. 24.↵
    2. Delfanti RL,
    3. Piccioni DE,
    4. Handwerker J, et al

    . Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status. J Neurooncol 2017;135:601–09 doi:10.1007/s11060-017-2613-7 pmid:28871469

    CrossRefPubMed
25. 25.↵
    2. McDonald CR,
    3. Delfanti RL,
    4. Krishnan AP, et al

    . Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma. Neuro Oncol 2016;18:1579–90 doi:10.1093/neuonc/now063 pmid:27106406

    CrossRefPubMed
26. 26.↵
    2. Jovicich J,
    3. Czanner S,
    4. Greve D, et al

    . Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. Neuroimage 2006;30:436–43 doi:10.1016/j.neuroimage.2005.09.046 pmid:16300968

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Nachimuthu DS,
    3. Baladhandapani A

    . Multidimensional texture characterization: on analysis for brain tumor tissues using MRS and MRI. J Digit Imaging 2014;27:496–506 doi:10.1007/s10278-013-9669-5 pmid:24496552

    CrossRefPubMed
28. 28.↵
    2. Li X,
    3. Xia H,
    4. Zhou Z, et al

    . 3D texture analysis of hippocampus based on MR images in patients with Alzheimer disease and mild cognitive impairment. In: Proceedings of the 3rd International Conference on Biomedical Engineering and Informatics, Yantai, China. October 16–18, 2010;1:1–4
29. 29.↵
    2. Suoranta S,
    3. Holli-Helenius K,
    4. Koskenkorva P, et al

    . 3D texture analysis reveals imperceptible MRI textural alterations in the thalamus and putamen in progressive myoclonic epilepsy type 1, EPM1. PLoS One 2013;8:e69905 doi:10.1371/journal.pone.0069905 pmid:23922849

    CrossRefPubMed
30. 30.↵
    2. Zhang J,
    3. Yu C,
    4. Jiang G, et al

    . 3D texture analysis on MRI images of Alzheimer's disease. Brain Imaging Behav 2012;6:61–69 doi:10.1007/s11682-011-9142-3 pmid:22101754

    CrossRefPubMed
31. 31.↵
    2. Ellingson BM,
    3. Cloughesy TF,
    4. Lai A, et al

    . Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011;13:401–09 doi:10.1093/neuonc/noq206 pmid:21324937

    CrossRefPubMed
32. 32.↵
    2. de Groot JF,
    3. Fuller G,
    4. Kumar AJ, et al

    . Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010;12:233–42 doi:10.1093/neuonc/nop027 pmid:20167811

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Narayana A,
    3. Kelly P,
    4. Golfinos J, et al

    . Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 2009;110:173–80 doi:10.3171/2008.4.17492 pmid:18834263

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Claes A,
    3. Idema AJ,
    4. Wesseling P

    . Diffuse glioma growth: a guerilla war. Acta Neuropathol 2007;114:443–58 doi:10.1007/s00401-007-0293-7 pmid:17805551

    CrossRefPubMedWeb of Science